Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
GLUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.21 - $12.40
Previous CloseN/A
Volume283.19K
Average Volume (3M)723.66K
Market Cap
$239.27M
Enterprise Value$97.43M
Total Cash (Recent Filing)-$6.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.20
Next Earnings
May 08, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding61,509,823
10 Day Avg. Volume1,010,485
30 Day Avg. Volume723,661
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.80
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.66
Enterprise Value/Ebitda-0.80
Forecast
1Y Price Target
$15.60Price Target Upside301.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical DataGLUE shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of >90% and substantial ablation of T and B cell function.
CollaborationsGLUE announced a collaborative agreement with Novartis to develop its first in class VAV1-degrader program MRT-6160.
Efficacy SignalsMonte Rosa plans to expand enrollment of their CRPC cohort to n=20-30 patients if a positive efficacy signal continues to be observed.
Bears Say
Limited UpsideThe decision to partner MRT-6160 limits material upside for the stock on the upcoming Phase 1 readout.
Patient EnrollmentThere is concern that the MRT-2359 Ph1 update may have too few patients to fully interpret its profile.
Pipeline ConcernsThe remainder of GLUE's pipeline remains early, with no expectations for significant stock-moving clinical data from other pipeline projects in 2025.
---
Ownership Overview
22.89% Insiders
20.99% Mutual Funds
39.96% Other Institutional Investors
7.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $3.21 and its highest was $12.40 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $239.27M.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 33 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Mar 20, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.016 by $0.144.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 61,509,823 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of $0.16 in its last earnings report, beating expectations of $0.016. Following the earnings report the stock price went up 5.373%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
---
Monte Rosa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.60 (301.03% Upside)
$15.60 (301.03% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 5.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $58.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.86%
12-Months-Change
Fundamentals
Return on Equity
-36.15%
Trailing 12-Months
Asset Growth
44.44%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
---
GLUE Company Deck
---
GLUE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Read More>---
GLUE Stock 12 Month Forecast
Average Price Target
$15.60
▲(301.03% Upside)
Technical Analysis
Fate Therapeutics
―
Ultragenyx Pharmaceutical
―
Arvinas Holding Company
―
Revolution Medicines
―
Kymera Therapeutics
―
Best Analysts Covering GLUE
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
+4.33%
reiterated a buy rating 17 days ago
Copying Eric Joseph's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +4.33% per trade.
---